89bio Provides Business Outlook for 2021

 -Phase 2b NASH trial as part of a potential Phase 2b/3 program expected to initiate in 1H21-

-Topline data from recently initiated NASH paired-biopsy, open-label histology cohort expected by YE21-

-Topline data from BIO89-100’s Phase 2 SHTG trial expected in 2H21-

http://www.globenewswire.com/news-release/2021/01/05/2153441/0/en/89bio-Provides-Business-Outlook-for-2021.html